Dyne Therapeutics Q3 2026: A $193M Loss Ahead of a Critical FDA Date
As seen on the 24/7 Wall St. homepage on November 5, 2026.
The loss widened, missing expectations, because Dyne is spending ahead of a launch it doesn't have yet: G&A more than doubled to $35.3 million on headcount for z-rostudirsen, whose FDA decision lands January 21, 2027. Cash of $1.13 billion funds operations into the second quarter of 2028, making the approval the whole story.
Continue ReadingShow less
Dyne Therapeutics posted a GAAP loss of $1.06 per share in the third quarter of 2026, missing expectations of $0.88. The quarterly net loss swelled to $193.55 million from $108.04 million in the same period a year earlier, as the company accelerated spending on late-stage clinical trials and the groundwork for a commercial launch it does not yet have regulatory clearance to execute.
The biggest driver on the cost side was research and development, where expenses climbed to $161.74 million from $97.22 million a year ago. That increase reflects higher manufacturing costs for z-rostudirsen and the ongoing expense of running the Phase 3 FORZETTO and HARMONIA trials. General and administrative costs nearly doubled as well, rising to $35.33 million from $16.7 million, as Dyne added headcount and infrastructure specifically to prepare for a potential z-rostudirsen launch.
Everything now points to January 21, 2027, the PDUFA target action date for z-rostudirsen under FDA priority review. The drug targets exon 51 Duchenne muscular dystrophy patients, and an approval by that date would trigger a planned U.S. commercial launch in the first quarter of 2027. The entire investment thesis for Dyne rests heavily on that single regulatory outcome.
Sponsored
On the DM1 side, Dyne expects topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in the first quarter of 2027. A positive readout there would support a potential BLA submission for U.S. Accelerated Approval in the third quarter of 2027, with a possible U.S. launch in the first half of 2028. The HARMONIA Phase 3 trial, described as the only Phase 3 DM1 trial currently enrolling, is running in parallel.
Dyne ended the quarter with $1.134 billion in cash, cash equivalents and marketable securities, which the company projects will fund operations into the second quarter of 2028. That runway is enough to absorb the current pace of spending and carry the company through both near-term data readouts, but it leaves little margin if approvals are delayed or trials disappoint. The EPS history also shows a pattern of spending acceleration: after relatively contained losses through 2025, the per-share loss jumped sharply in Q1 2026 and again in Q3 2026, reflecting the ramp into commercial readiness.
Mentioned: DYN